3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Fallopian Tube Neoplasms
10
Ovarian Neoplasms
7
Endometrial Neoplasms
5
Breast Neoplasms
4
Prostatic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Neuroblastoma
2
Neoplasms
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Interventions
Cisplatin
4
Radiotherapy
3
Cetuximab
3
pembrolizumab
2
Surveys and Questionnaires
2
Carboplatin
2
olaparib
1
niraparib
1
fludarabine
1
dostarlimab
1
cemiplimab
1
calcipotriene
1
avelumab
1
atezolizumab
1
aldesleukin
1
Watchful Waiting
1
Tiragolumab
1
Standard of Care
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Platinum
1
Phlebotomy
1
Paclitaxel
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Fluorouracil
1
Fluorodeoxyglucose F18
1
Docetaxel
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
olaparib
×
30 days
×
Clear all
NCT02308072
2026-05-22
ORCA-2
University College, London
Phase 1
Completed
16 enrolled